Irrational exuberance in clinical proteomics

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 7963-7964

  Lin, Simon M ^a   Kibbe, Warren Alden ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

BIOSTATISTICS; CALIBRATION; DNA MICROARRAY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; FOOD AND DRUG ADMINISTRATION; HELICOBACTER PYLORI; HIGH THROUGHPUT SCREENING; INVESTMENT; MASS SPECTROMETRY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARDIZATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BLOOD PROTEINS; ESOPHAGEAL NEOPLASMS; HUMANS; PREDICTIVE VALUE OF TESTS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 28144441793     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1744     Document Type: Editorial

References (12)

1. Hayashida Y. Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling, this issue; 2005:11:8042-7.
2. Irizarry RA. Multiple Lab Comparison of Microarray Platforms. Johns Hopkins University, Dept. of Biostatistics Working Paper 71, http://www.bepress.com/ jhubiostat/paper71; 2004.
3. Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-12.
4. Cope LM, Irizarry RA, Jaffee HA, Wu Z, Speed TP. A benchmark for Affymetrix GeneChip expression measures. Bioinformatics 2004;20:323-31.
5. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF, Jr. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 2003;3:1720-4.
6. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-8.
7. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14,
8. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 2003;362: 1439-44.
9. Ball C, Brazma A, Causton H, et al. An open letter on microarray data from the MGED Society. Microbiology 2004;150:3522-4.
10. Orchard S, Hermjakob H, Julian RK, Jr., et al. Common interchange standards for proteomics data: public availability of tools and schema. Proteomics 2004;4:490-1.
11. Kopans DB. Gene-expression signatures in breast cancer. N Engl J Med 2003;348:1715-7; author reply 1715-7.
12. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005;54 Suppl 1:i1-5.